Key Takeaways:
- Advanced BioScience Laboratories (ABL) secures a groundbreaking seven-year contract worth $98.9 million from the National Institutes of Health (NIH) Division of AIDS (DAIDS) to advance HIV prevention science.
- ABL will provide essential services, including preclinical research support, development of pediatric formulations, and the advancement of next-generation non-vaccine Biomedical HIV Prevention products (nBPs).
- The contract aims to address the global challenge of HIV transmission by developing safe, effective, and acceptable prevention and treatment products, particularly for the underserved pediatric population.
Advancing HIV Prevention Science through Collaboration
Rockville, MD, United States, May 23, 2023 – Advanced BioScience Laboratories (ABL), a globally recognized Contract Development and Manufacturing Organization (CDMO) specializing in biotherapies, oncolytics, and viral vector vaccines, proudly announces its recent contract award by the National Institutes of Health (NIH) Division of AIDS (DAIDS). The contract, titled “Resources to Advance Pediatrics and HIV Prevention Science (RAPPS),” holds immense promise for the future of HIV prevention and pediatric healthcare.
Meeting Critical Needs in HIV Prevention
With a total potential funding value of $98.9 million, the seven-year contract empowers ABL to play a pivotal role in advancing preclinical research, pediatric formulations, and next-generation non-vaccine Biomedical HIV Prevention products (nBPs). ABL’s comprehensive suite of services will encompass preclinical gap-filling, animal models, bioanalytical services, product manufacturing, and various other scientific and quality/regulatory support activities.
The primary focus of the contract is to develop innovative prevention products that can revolutionize the fight against HIV. Among the promising solutions are IntraVaginal Rings (IVRs), long-acting injectables, and Multipurpose Prevention Technologies (MPTs), which combine drugs to target the prevention of pregnancy, Sexually Transmitted Infections (STIs), and HIV transmission.
Addressing the Global HIV Challenge
According to the World Health Organization (WHO), more than 38 million individuals worldwide are living with HIV, with approximately 4,000 new infections occurring daily. The development of safe, effective, and accessible products to prevent and treat HIV is crucial in curbing the spread of the disease globally. Women and girls, who represent 53% of all people living with HIV, are disproportionately affected. Despite advancements in treatment and prevention regimens, limited access and poor product adherence remain significant barriers, particularly for at-risk populations.
ABL’s expertise will be instrumental in supporting DAIDS’ efforts to develop and advance promising HIV prevention products for the pediatric population. Notably, only a fraction of AntiRetroViral (ARV) drugs approved for adults are currently approved for children under the age of two. By addressing this critical gap, ABL and DAIDS aim to improve health outcomes and reduce HIV transmission among vulnerable children.
Continuing Collaboration for a Brighter Future
ABL’s relationship with DAIDS dates back to the 1980s when ABL scientists actively contributed to HIV pathogenesis research, therapeutics development, and vaccine advancements. This new contract strengthens their historic partnership, positioning ABL as a collaborative bridge between DAIDS and innovative investigators in the field.
Peter Silvera, Principal Investigator of Innovation and Translation at ABL, expresses enthusiasm for the contract, emphasizing ABL’s commitment to serving the pediatric population and working towards preventing, treating, and ultimately curing HIV. Through its cutting-edge capabilities and collaborative approach, ABL is poised to make significant strides in the fight against HIV and improve the lives of millions worldwide.
About the National Institutes of Health (NIH)
As the primary federal agency for medical research, the NIH comprises 27 institutes and centers and operates under the U.S. Department of Health and Human Services. The NIH conducts and supports basic, clinical, and translational medical research to investigate the causes, treatments, and cures for both common and rare diseases.
About Advanced BioScience Laboratories (ABL)
ABL, Inc. is a globally recognized Contract Research and Manufacturing Organization (CDMO) dedicated to advancing therapeutics, vaccines, and other biological products. With extensive experience working with diverse organizations including industry, government, and academic entities, ABL specializes in biotherapies, oncolytics, and viral vector vaccines. The company maintains state-of-the-art facilities meeting international regulatory standards, providing manufacturing capabilities for virus-based therapies, gene therapies, and viral vaccines. ABL’s services encompass bulk drug substance production, live virus fill/finish, process and assay development, as well as preclinical and clinical sample processing and testing through its immunological laboratories. ABL is proud to be part of the Institut Mérieux group of companies, dedicated to global translational science for enhanced patient care.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at [email protected] to get started!
